Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.41 - isocitrate dehydrogenase (NAD+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1).
Inactivation of metabolic enzymes by photo-treatment with zinc meta N-methylpyridylporphyrin.
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer.
Adenocarcinoma of Lung
Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18 F]FDG.
Adenoma, Oxyphilic
MicroRNAs as Urinary Biomarker for Oncocytoma.
alpha-Thalassemia
In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates.
Arthritis
Oxidative state and oxidative metabolism of the heart from rats with adjuvant-induced arthritis.
Asthenozoospermia
Mobile phones electromagnetic radiation and NAD+-dependent isocitrate dehydrogenase as a mitochondrial marker in asthenozoospermia.
Astrocytoma
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation.
A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
Adult IDH wild-type lower-grade gliomas should be further stratified.
Analysis of Cellular Feature Differences of Astrocytomas with Distinct Mutational Profiles Using Digitized Histopathology Images.
Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia.
Awake Craniotomy and Resection of a Left Frontal High-Grade Glioma: 2-Dimensional Operative Video.
Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients.
Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma.
Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
Clinical implications of molecular analysis in diffuse glioma stratification.
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas.
Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry.
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
Diffuse low-grade glioma mimicking ischaemic infarct: a case report.
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Exploiting Metabolic Differences in Glioma Therapy.
Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.
Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas.
Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas.
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
IDH mutations in older patients with diffuse astrocytic gliomas.
IDH-1 polymorphisms in pilocytic astrocytomas.
IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Integrated genomic and transcriptomic analysis suggests KRT18 mutation and MTAP are key genetic alterations related to the prognosis between astrocytoma and glioblastoma.
Integrated molecular characterization of IDH-mutant glioblastomas.
KIAA1549-BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults.
Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2.
Lower Grade Gliomas.
Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis by MicroRNA183-mediated inhibition of Semaphorin 3E.
Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.
Mutant metabolic enzymes are at the origin of gliomas.
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.
Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism.
Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.
Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors.
Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients.
Promoter Methylation Analysis of IDH Genes in Human Gliomas.
Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Surgery of Insular Diffuse Gliomas-Part 1: Transcortical Awake Resection Is Safe and Independently Improves Overall Survival.
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts.
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients.
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.
The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
WT1 in astrocytomas: Comprehensive evaluation of immunohistochemical expression and its potential utility in different histological grades.
[Update on primary brain tumours].
Ataxia Telangiectasia
ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Biliary Tract Diseases
[Isocitrate dehydrogenase activity in liver and biliary tract diseases as an indicator of liver cell necrosis]
Biliary Tract Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Blindness
A novel variant in IDH3A identified in a case with Leber congenital amaurosis accompanied by macular pseudocoloboma.
Bone Marrow Failure Disorders
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
Brain Diseases
Homozygous mutation, p.Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy.
Brain Injuries, Traumatic
Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury.
Brain Neoplasms
A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.
Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma.
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors
Cancer metabolism as a central driving force of glioma pathogenesis.
Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning.
Contemporary Mouse Models in Glioma Research.
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation.
Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Isocitric dehydrogenase of the cerebrospinal fluid in brain tumours and meningitis.
Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system.
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas.
Radiomics, Metabolic, and Molecular MRI for Brain Tumors.
Recent aspects of classification and epidemiology of epilepsy-associated tumors.
Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.
Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Updates in prognostic markers for gliomas.
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.
[Update on primary brain tumours].
Breast Neoplasms
ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.
Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling.
Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
[Activity of isocitrate dehydrogenase in breast cancer]
[Biochemical behavior of pyruvate kinase, LDH, isocitrate dehydrogenase and malate dehydrogenase in breast carcinomas]
Carcinogenesis
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Isocitrate dehydrogenase mutations in leukemia.
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Metabolic changes in cancer: beyond the Warburg effect.
Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm.
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
New Directions in the Treatment of Glioblastoma.
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Suppression of tumorigenesis in mitochondrial NADP(+)-dependent isocitrate dehydrogenase knock-out mice.
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State.
The role of NAD(+)-dependent isocitrate dehydrogenase 3 subunit ? in AFB1 induced liver lesion.
Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations.
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.
Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
[The role of lipid metabolism disorders, atypical isoforms of protein kinase C, and mutational status of cytosolic and mitochondrial forms of isocitrate dehydrogenase in carcinogenesis of glial tumors].
Carcinoma
Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Diphosphopyridine nucleotide specific isocitric dehydrogenase of mammalian mitochondria. II. Kinetic properties of the enzyme of the Ehrlich ascites carcinoma.
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Emerging molecular therapeutic targets for cholangiocarcinoma.
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
MicroRNAs as Urinary Biomarker for Oncocytoma.
NAD-dependent isocitrate dehydrogenase as a novel target of tributyltin in human embryonic carcinoma cells.
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Serum enzymes in disease V. Isocitric dehydrogenase, malic dehydrogenase, and glycolytic enzymes in patients with carcinoma of the breast.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.
The Roles of 2-Hydroxyglutarate.
Tributyltin induces G2/M cell cycle arrest via NAD(+)-dependent isocitrate dehydrogenase in human embryonic carcinoma cells.
Tributyltin induces mitochondrial fission through NAD-IDH dependent mitofusin degradation in human embryonic carcinoma cells.
[Histoenzymatic studies of carcinoma of the cervix (lactic dehydrogenase, malic dehydrogenase, isocitric dehydrogenase and succinic dehydrogenase)]
Carcinoma, Basal Cell
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Carcinoma, Ehrlich Tumor
Enzyme activities of six different dehydrogenases in Ehrlich ascites cells measured by flow cytometry.
Carcinoma, Hepatocellular
A pilot study on the screening of primary hepatocellular carcinoma in selected high risk groups in the population using multiple tumour markers.
Chemopreventive efficacy of selenium against N-nitrosodiethylamine-induced hepatoma in albino rats.
Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients.
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Carcinoma, Renal Cell
The Roles of 2-Hydroxyglutarate.
Carcinoma, Squamous Cell
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Cardiotoxicity
A possible mechanism of adriamycin cardiotoxicity. Inhibition of NADP-linked isocitrate dehydrogenase.
Cataract
[Malate dehydrogenase and TPN-specific isocitrate dehydrogenase in human cataract lenses]
Central Nervous System Neoplasms
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Chemical and Drug Induced Liver Injury
[Activity of liver mitochondrial NAD+-dependent dehydrogenases of the krebs cycle in rats with acetaminophen-induced hepatitis developed under conditions of alimentary protein deficiency].
Cholangiocarcinoma
Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
The implications of IDH mutations for cancer development and therapy.
Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma.
Cholecystitis
HIGH SERUM TRANSAMINASE AND ISOCITRIC DEHYDROGENASE LEVELS IN A PATIENT WITH CHOLECYSTITIS AND SUBACUTE HEPATITIS.
Cholestasis
Relationship between antioxidant systems, intracellular thiols and DNA ploidy in liver of rats during experimental cirrhogenesis.
Chondroma
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Chondrosarcoma
An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Current questions in bone sarcomas.
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prognostic impact of IDH mutations in chondrosarcoma.
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
The implications of IDH mutations for cancer development and therapy.
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Colonic Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Targeting cancer metabolism.
Colorectal Neoplasms
Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome.
Coma
Effect of total hepatectomy on selected cerebral substrates and enzymes of the glycolytic pathways and Krebs cycle.
[Changes of some energy exchange parameters in the rat heart under insulin hypoglycemia]
[Energy metabolic changes and nerve cell damage in rats exposed to multiple administration of large-dose insulin].
Congenital Abnormalities
IDH2-deficient mice develop spinal deformities with aging.
Cysts
MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
Sarcocystis fusiformis: some Krebs cycle enzymes in various fractions of sarcocysts of buffalo (Bubalus bubalis).
Dehydration
Crystal structure of the monomeric isocitrate dehydrogenase in the presence of NADP+: insight into the cofactor recognition, catalysis, and evolution.
Diabetes Mellitus
Metabolism and ultrastructure in ovaries of alloxan-diabetic juvenile rats.
Diabetic Nephropathies
Effect of yam (Dioscorea cayenensis) and dasheen (Colocassia esculenta) extracts on the kidney of streptozotocin-induced diabetic rats.
Digestive System Diseases
Glycylprolyl-p-nitroanilidase in hepatobiliary disease.
[Determination of serum isocitrate dehydrogenase in patients with hepatobiliary diseases]
[Diagnostic significance of serum isocitrate dehydrogenase in hepatobiliary diseases]
[Isocitric dehydrogenase in hepatobiliary diseases]
Down Syndrome
Mitochondrial enzyme deficiencies in Down's syndrome.
Dystonia
[Activity of oxidative enzymes during dosed exercise in healthy persons and in persons with neurocirculatory dystonia]
Enchondromatosis
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Endometrial Neoplasms
Biochemical changes in endometrial carcinoma and their correlation to clinical outcome and prognosis.
The effects of PGC-1? on the proliferation and energy metabolism of malignant endometrial cancer cells.
Ependymoma
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Epilepsy
Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Esophageal Squamous Cell Carcinoma
Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.
Fatty Liver
Biochemical changes associated with the fatty liver syndrome in cows.
Prevention of CCl4-induced liver necrosis by the calcium chelator arsenazo III.
Gallbladder Neoplasms
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Gallstones
Identification of Helicobacter pylori DNA in Iranian patients with gallstones.
Gastritis
Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis.
Giant Cell Tumor of Bone
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Giant Cell Tumors
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Gingivitis
Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis.
Glioblastoma
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
A new functional IDH2 genetic variant is associated with the risk of lung cancer.
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells.
Analysis of the IDH1 codon 132 mutation in brain tumors.
Anaplastic ganglioglioma with epithelioid cell components.
Antidepressant drug use in glioblastoma patients: an epidemiological view.
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma.
BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Cancer metabolism as a central driving force of glioma pathogenesis.
Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.
Clinical implications of hypoxia-inducible factor-1? and caveolin-1 overexpression in isocitrate dehydrogenase-wild type glioblastoma multiforme.
Clinical importance of molecular markers of adult diffuse glioma.
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres.
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns.
Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma.
Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival.
Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features.
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM.
Detection of Isocitrate Dehydrogenase Mutated Glioblastomas Through Anomaly Detection Analytics.
Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features.
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas.
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.
Expanding the spectrum of IDH1 mutations in gliomas.
EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.
Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.
Glioblastoma.
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Gliosarcoma: Neuroimaging and Immunohistochemical Findings.
Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?
High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme.
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status.
IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
IFI30 expression is an independent unfavourable prognostic factor in glioma.
Immunotherapy for secondary glioblastoma multiforme: toward an isocitrate dehydrogenase vaccine.
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-acetate PET imaging.
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma.
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
Integrated metabolomics and lipidomics analyses reveal metabolic reprogramming in human glioma with IDH1 mutation.
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas.
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.
Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications.
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
Label-free highly sensitive detection of DNA approximate length and concentration by impedimetric CRISPR-dCas9 based biosensor technology.
Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3?
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations.
Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
Management of Elderly Patients with Glioblastoma.
Management of glioblastoma: State of the art and future directions.
Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating ?-oxygenation pathway in colorectal cancer.
Metabolic Reprogramming in Mutant IDH1 Glioma Cells.
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma.
Molecular targeted therapy of glioblastoma.
MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial.
MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas.
Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project.
Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.
Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence.
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells.
Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.
N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma.
Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome.
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.
O(6)-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.
O6-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma.
Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis.
Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Papillary glioblastoma exhibiting a neuroradiological cyst with a mural nodule: A case report.
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making.
Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Primary Focal Intracranial Leptomeningeal Glioma: Case Report and Review of the Literature.
Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Promoter Methylation Analysis of IDH Genes in Human Gliomas.
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Radiogenomic modeling predicts survival-associated prognostic groups in glioblastoma.
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas.
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma.
Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.
Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma.
Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.
Solitary primary intracranial leptomeningeal glioblastoma invading the normal cortex: Case report.
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma.
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Surgery of Insular Diffuse Gliomas-Part 1: Transcortical Awake Resection Is Safe and Independently Improves Overall Survival.
Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients.
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.
The Role of Delayed Radiotherapy Initiation in Patients with Newly Diagnosed Glioblastoma with Residual Tumor Mass.
Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment.
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
[Glioblastoma with BRAFV600E mutation and numerous metastatic foci: a case report].
[Update on primary brain tumours].
Glioma
11C-Methionine Integrated PET/MRI-Based Texture Analysis Features May Have a Potential Ability to Distinguish Oligodendroglioma (IDH-Mutant and 1p/19q-Codeleted) From Varied Gliomas.
18F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T.
2-hydroxyglutarate MR Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-analysis using Individual Patient Data.
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
A comparative study of short- and long-TE (1) H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
A comparison of 2-hydroxyglutarate detection at 3 and 7 T with long-TE semi-LASER.
A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation.
A Linearized Fit Model for Robust Shape Parameterization of FET-PET TACs.
A new functional IDH2 genetic variant is associated with the risk of lung cancer.
A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
A Non-invasive Radiomic Method Using 18F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma.
A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy.
A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas.
A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.
A vaccine targeting mutant IDH1 induces antitumour immunity.
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma.
Accelerated progression of IDH mutant glioma after first recurrence.
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study.
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
Anaplastic gliomas in adults: an update.
Anaplastic oligodendroglioma metastasizing to the bone marrow: a unique case report and literature review.
Anaplastic Oligodendroglioma with Transdural Extension.
Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Association between IDH1/2 mutations and brain glioma grade.
Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.
Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival.
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.
Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.
ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/?-Catenin Signaling in IDH1-mutant Gliomas.
Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign.
Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6 -methylguanine-DNA methyltransferase promoter methylation in patients with gliomas.
B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Biomarker-driven diagnosis of diffuse gliomas.
BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Brain Tumors of Glial Origin.
Cancer metabolism as a central driving force of glioma pathogenesis.
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.
Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields.
Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol.
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Cerebellar high-grade astrocytoma with IDH mutations in the elderly: A report of two cases.
Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology.
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning.
Clinical implications of molecular analysis in diffuse glioma stratification.
Clinical importance of molecular markers of adult diffuse glioma.
Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Commentary: The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study.
Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas.
Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.
Contemporary Mouse Models in Glioma Research.
Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
CTLA-4 correlates with immune and clinical characteristics of glioma.
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.
D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
Deep cross-view co-regularized representation learning for glioma subtype identification.
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis.
Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?
Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.
Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.
Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification.
Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Diffuse gliomas in patients aged 55?years or over: A suggestion for IDH mutation testing.
Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.
Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival.
DNA methylation in adult diffuse gliomas.
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Dynamic 18F-Fluoro-Ethyl-Tyrosine Positron Emission Tomography/ Computed Tomography: A Better Predictor of Isocitrate Dehydrogenase Mutation in Presurgical Evaluations of Glioma.
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.
Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
Editorial for "Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features".
EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma.
Elevated expression of fatty acid synthase and nuclear localization of carnitine palmitoyltransferase 1C are common among human gliomas.
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Emerging interplay of genetics and epigenetics in gliomas: a new hope for targeted therapy.
Emerging targets for anticancer vaccination: IDH.
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas.
Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience.
Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.
Expanding the spectrum of IDH1 mutations in gliomas.
Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling.
Expression of m6A Regulators Correlated With Immune Microenvironment Predicts Therapeutic Efficacy and Prognosis in Gliomas.
Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.
Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
FGFR-TACC gene fusions in human glioma.
FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma.
Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1 H-MRS.
Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples.
Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics.
Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Gene markers in brain tumors: what the epileptologist should know.
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Genotyping low-grade gliomas among Hispanics.
Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.
Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Glioma-derived mutations in IDH: from mechanism to potential therapy.
Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
Glioma.
Glutamate and ?-ketoglutarate: key players in glioma metabolism.
Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?
GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.
Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas.
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma.
High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma.
Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.
Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas.
Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.
Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Identification of IDH and TERTp mutation status using 1 H-MRS in 112 hemispheric diffuse gliomas.
Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
IDH mutation in glioma: new insights and promises for the future.
IDH mutation-specific radiomic signature in lower-grade gliomas.
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
IDH-Mutant Brain Tumors Hit the Achilles' Heel of Macrophages with R-2-Hydroxyglutarate.
IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature.
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
IDH1 and IDH2 Mutations in Gliomas.
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature.
IDH1 Non-Canonical Mutations and Survival in Patients with Glioma.
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.
IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma.
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1?mutant tumor cells.
IDH2 Deficiency in Microglia Decreases the Pro-inflammatory Response via the ERK and NF-?B Pathways.
IDH2 mutation in gliomas including novel mutation.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1?-regulated pseudohypoxic state.
IFI30 expression is an independent unfavourable prognostic factor in glioma.
IGFBP2 expression predicts IDH-mutant glioma patient survival.
IKBIP is a novel EMT-related biomarker and predicts poor survival in glioma.
Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Immune-related genes with APA in microenvironment indicate risk stratification and clinical prognosis in grade II/III gliomas.
Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Immunotherapy in gliomas: Are we reckoning without the innate immunity?
Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
In vivo Metabolic Profiles as Determined by
In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma.
Increased RLIP76 expression in IDH1 wild?type glioblastoma multiforme is associated with worse prognosis.
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Integrated metabolomics and lipidomics analyses reveal metabolic reprogramming in human glioma with IDH1 mutation.
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer.
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.
Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients.
Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas.
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development.
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications.
Isocitrate dehydrogenase mutations in gliomas.
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients.
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas.
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.
Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma.
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
Kiaa0101 serves as a prognostic marker and promotes invasion by regulating p38/snail1 pathway in glioma.
KIAA1549-BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults.
Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3?
Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations.
Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Low-grade gliomas.
Low-grade Gliomas.
Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.
Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status.
Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.
Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas.
Magnetic Resonance Spectrobiopsy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma.
Magnetic Resonance Spectroscopic Assessment of IDH Status in gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics.
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.
Magnetic Resonance Spectroscopy for Identification of Isocitrate Dehydrogenase Mutation in Gliomas.
Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile.
Malignant clinical features of anaplastic gliomas without IDH mutation.
Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Management of diffusely infiltrating glioma in the elderly.
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Metabolic profiling of human gliomas assessed with NMR.
Metabolic Reprogramming in Mutant IDH1 Glioma Cells.
Metabolic reprogramming in the pathogenesis of glioma: Update.
Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
MicroRNA-183 upregulates HIF-1? by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells.
MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.
Mitochondrial dysfunction in gliomas.
Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.
MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells.
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Molecular classification of adult gliomas: recent advances and future perspectives.
Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma.
Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.
MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization.
MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas.
mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma.
Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Multicenter DSC-MRI-Based Radiomics Predict IDH Mutation in Gliomas.
Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas.
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study.
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria.
Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
Mutant IDH1 regulates the tumor-associated immune system in gliomas.
Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence.
Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor??B activation in a hypoxia?inducible factor 1?? dependent manner.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
Neuro-oncology: Five new things.
Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.
New treatment paradigm for patients with anaplastic oligodendroglial tumors.
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
Non-Invasive Estimation of Glioma IDH1 Mutation and VEGF Expression by Histogram Analysis of Dynamic Contrast-Enhanced MRI.
Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning.
Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review.
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Novel IDH1-Targeted Glioma Therapies.
Novel ways to target brain tumour metabolism.
O(6)-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.
Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas.
Oncogenic ZEB2/miR-637/HMGA1 signaling axis targeting vimentin promotes the malignant phenotype of glioma.
Oncometabolites: tailoring our genes.
Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
p62 acts as an oncogene and is targeted by miR-124-3p in glioma.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-wild-type Diffuse Astrocytic Gliomas.
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas.
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction.
Peripheral Inflammatory Blood Markers in Diagnosis of Glioma and IDH Status.
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Perspectives on IDH Mutation in Diffuse Gliomas.
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.
Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016.
Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients.
Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Predicting IDH genotype in gliomas using FET PET radiomics.
Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images.
Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.
Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study.
Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival.
Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas.
Protein Markers Predict Survival in Glioma Patients.
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival.
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis.
Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
Radiomics, Metabolic, and Molecular MRI for Brain Tumors.
Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas.
Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies.
Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer.
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry.
Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy.
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.
Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.
Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
Relationship of Molecular Genetic Tumor Marker IDH with Oxidative Status in Gliomas.
Relaxometry and quantification in sodium MRI of cerebral gliomas: A FET-PET and MRI small-scale study.
Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
Reverse Engineering Glioma Radiomics to Conventional Neuroimaging.
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Role of isocitrate dehydrogenase in glioma.
Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
Rosette-Forming Glioneuronal Tumor Originating From the Spinal Cord: Report of 2 Cases and Literature Review.
RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
Silencing of mitochondrial NADP(+)-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity.
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.
Static and dynamic
Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET.
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Targeted Therapies in Rare Brain Tumours.
Targeting cancer metabolism.
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).
TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma.
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
The association between 11C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas.
The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner.
The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.
The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
The epidemiology of glioma in adults: a "state of the science" review.
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.
The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
The implications of IDH mutations for cancer development and therapy.
The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
The prognostic significance of p16 expression pattern in diffuse gliomas.
The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.
The role of APT imaging in gliomas grading: A systematic review and meta-analysis.
The Role of the T2-FLAIR Mismatch Sign as an Imaging Marker of IDH Status in a Mixed Population of Low- and High-Grade Gliomas.
The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas.
Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase (IDH) mutations in gliomas.
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas.
Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma.
Treatment of anaplastic glioma.
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Updates in prognostic markers for gliomas.
Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma.
Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment.
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.
Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma.
World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.
World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.
[Analysis of the clinical impact of the diagnostic reclassification of brain gliomas according to the World Health Organization classification (2016)].
[Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
[The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
Gliosarcoma
An IDH1-mutated primary gliosarcoma: case report.
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells.
Clinicopathologic and genomic features of gliosarcomas.
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Molecular and clonal evolution in recurrent metastatic gliosarcoma.
Head and Neck Neoplasms
Targeting metabolic pathways for head and neck cancers therapeutics.
Hearing Loss
SIRT3 in calorie restriction: can you hear me now?
Heart Failure
Mitochondrial Bioenergetics and Dysfunction in Failing Heart.
Proteomic analysis of left ventricular remodeling in an experimental model of heart failure.
Hemangioma
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Hematologic Neoplasms
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Familial hematological malignancies: new IDH2 mutation.
IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.
Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating ?-oxygenation pathway in colorectal cancer.
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Hepatitis
HIGH SERUM TRANSAMINASE AND ISOCITRIC DEHYDROGENASE LEVELS IN A PATIENT WITH CHOLECYSTITIS AND SUBACUTE HEPATITIS.
Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism.
Studies on transmission of human non-A, non-B hepatitis to marmosets.
[Activity of liver mitochondrial NAD+-dependent dehydrogenases of the krebs cycle in rats with acetaminophen-induced hepatitis developed under conditions of alimentary protein deficiency].
[Behavior of serum isocitrate dehydrogenase in subjects with viral hepatitis after treatment with lysozyme]
[Study on the behavior of serum isocitrate dehydrogenase. In subjects affected by viral hepatitis]
[The value of isocitric dehydrogenase in the differential diagnosis between viral hepatitis and Weil's disease.]
Hepatitis A
Comparison of activities of isocitric dehydrogenase and glutamic-oxalacetic transaminase in serum infectious hepatitis.
Herpes Simplex
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Hidradenitis Suppurativa
Reduced ten-eleven translocation and isocitrate dehydrogenase expression in inflammatory hidradenitis suppurativa lesions.
Hydrocephalus
Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Hyperglycemia
Metformin counteracts glucose-dependent lipogenesis and impairs transdeamination in the liver of gilthead sea bream (Sparus aurata).
Hyperhomocysteinemia
Homocysteine induces energy imbalance in rat skeletal muscle: Is creatine a protector?
Hypersensitivity
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Hypertension
Cardiac hypertrophy in spontaneously hypertensive rats.
Comparative analysis of renal protein expression in spontaneously hypertensive rat.
Isocitrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hypertension.
Hyperthyroidism
Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism.
Hypoglycemia
Cocklebur (Xanthium strumarium, L. var. strumarium) intoxication in swine: review and redefinition of the toxic principle.
Hypokinesia
[Activity of oxidative enzymes of the tricarboxylic acid cycle in the liver of rats during hypokinesia]
[Oxidative enzyme activity of the tricarboxylic acid cycle in rat skeletal muscles in hypokinesia]
Infections
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein.
Alterations in enzymatic activities of the intestinal mucosa during the course of Giardia lamblia infection in mice.
Alterations in metabolic pathways in gastric epithelial cells infected with Helicobacter pylori.
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Further investigations of race:cultivar-specific induction of enzymes related to phytoalexin biosynthesis in soybean roots following infection with Phytophthora megasperma f.sp. glycinea.
Inflammatory Bowel Diseases
Glycylprolyl-p-nitroanilidase in hepatobiliary disease.
Influenza, Human
Structural similarity between binding sites in influenza sialidase and isocitrate dehydrogenase: implications for an alternative approach to rational drug design.
Insulin Resistance
Increased obesity resistance and insulin sensitivity in mice lacking the isocitrate dehydrogenase 2 gene.
Intellectual Disability
In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates.
Iron Deficiencies
Bio-inorganic regulation of pathways of carbohydrate and lipid metabolism. II. The effect of iron-deficiency on the profile of enzymes in the developing rat adrenal gland.
Perturbation of mitochondrial composition in muscle by iron deficiency. Implications regarding regulation of mitochondrial assembly.
isocitrate dehydrogenase (nad+) deficiency
Isocitrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hypertension.
Isocitrate dehydrogenase 2 deficiency exacerbates dermis damage by ultraviolet-B via ?Np63 downregulation.
Isocitrate dehydrogenase 2 deficiency induces endothelial inflammation via p66sh-mediated mitochondrial oxidative stress.
Mitochondrial NADP(+)-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury.
Kwashiorkor
Serum transaminases and isocitric dehydrogenase in kwashiorkor.
Leber Congenital Amaurosis
A novel variant in IDH3A identified in a case with Leber congenital amaurosis accompanied by macular pseudocoloboma.
Leukemia
Alterations of Mitochondria and Related Metabolic Pathways in Leukemia: A Narrative Review.
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Genistein decreases cellular redox potential, partially suppresses cell growth in HL?60 leukemia cells and sensitizes cells to ??radiation?induced cell death.
Glutamate and ?-ketoglutarate: key players in glioma metabolism.
IDH mutation in glioma: new insights and promises for the future.
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1?-regulated pseudohypoxic state.
Isocitrate dehydrogenase mutations in leukemia.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Targeting cancer metabolism.
The role of autophagy in targeted therapy for acute myeloid leukemia.
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer.
[Behavior of serum isocitrate dehydrogenase in acute lymphatic leukemia of childhood]
[Research advances of IDH gene mutation and AML].
Leukemia, Myeloid
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Leukemia, Myeloid, Acute
2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
A Rare Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease That Transformed to Acute Leukemia With IDH2 Mutation.
A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling.
Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors
Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors.
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML.
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
D-2-hydroxyglutarate interferes with HIF-1? stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization.
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Epigenetic aberrations in myeloid malignancies (Review).
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
FDA Approval Summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia.
IDH Inhibitors in AML-Promise and Pitfalls.
IDH mutations in acute myeloid leukemia.
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1?mutant tumor cells.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.
Isocitrate dehydrogenase mutations in myeloid malignancies.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C?>?T have a prognostic value in acute myeloid leukemia.
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.
Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.
Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia.
The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia.
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.
Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome.
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study.
Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study.
[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Leukemia, Promyelocytic, Acute
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
The role of autophagy in targeted therapy for acute myeloid leukemia.
Leukocytosis
Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia.
Lipid Metabolism Disorders
[The role of lipid metabolism disorders, atypical isoforms of protein kinase C, and mutational status of cytosolic and mitochondrial forms of isocitrate dehydrogenase in carcinogenesis of glial tumors].
Liver Diseases
An evaluation of isocitric dehydrogenase in liver disease.
Falsely normal value in fluorometric transferase screening of galactosemic blood. A cautionary note.
Serum isocitrate dehydrogenase in liver disease and some other conditions.
Serum isocitric dehydrogenase activity in the differential diagnosis of liver disease.
Serum isocitric dehydrogenase activity with particular reference to liver disease.
[SERUM ENZYMES IN THE DIAGNOSIS OF LIVER DISEASE. III. SORBITOL DEHYDROGENASE, ALDOLASES, ISOCITRIC DEHYDROGENASE AND TRANSAMINASES.]
[STUDIES ON ISOCITRIC DEHYDROGENASE IN SERUM OF LIVER DISEASES.]
[STUDIES ON SERUM ISOCITRATE DEHYDROGENASE. II. IN LIVER DISEASES.]
[Studies on the enzymatic activity value of serum isocitrate dehydrogenase in pediatrics. 3. On the enzymatic activity value of serum isocitrate dehydrogenase in liver diseases in children.]
[The diagnostic importance of isocitrate dehydrogenase and of glutathione reductase in liver diseases.]
Lung Neoplasms
Effect of mangiferin on benzo(a)pyrene induced lung carcinogenesis in experimental Swiss albino mice.
IDH-Inhibiting Small Molecule DTDQ Inhibits Migration and Invasion of A549 Human Non-Small-Cell Lung Cancer Cells via Sequential Inactivation Of ERK and P38 Signaling Pathways.
Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer.
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Weak sharing of genetic association signals in three lung cancer subtypes: evidence at the SNP, gene, regulation, and pathway levels.
[Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Lymphoma
Myeloproliferative neoplasms: Current molecular biology and genetics.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Lymphoma, B-Cell
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.
Lymphoma, T-Cell
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Identification of cell-type-specific mutations in nodal T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
Identification of cell-type-specific mutations in nodal T-cell lymphomas.
Malaria
NADP-specific isocitrate dehydrogenase from the simian malaria parasite Plasmodium knowlesi: partial purification and characterization.
Malnutrition
[Activity of amylase, lipase and isocitrate dehydrogenase enzymes in cases of proteino-caloric malnutrition]
Medulloblastoma
Targeted Therapies in Rare Brain Tumours.
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Melanoma
5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
A Rare Case of Atypical Pleomorphic Neoplasm of Pineal Region in a Child: A Case Report.
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Mitochondrial NADP(+)-dependent isocitrate dehydrogenase knockdown inhibits tumorigenicity of melanoma cells.
Mutational status of IDH1 in uveal melanoma.
Proteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade.
Meningitis
Isocitric dehydrogenase of the cerebrospinal fluid in brain tumours and meningitis.
Metabolic Diseases
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Microcephaly
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Mouth Neoplasms
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Multiple Sclerosis
[DETERMINATION OF ISOCITRATE DEHYDROGENASE, LACTIC DEHYDROGENASE AND GLUTAMIC-OXALACETIC TRANSAMINASE IN THE CEREBROSPINAL FLUID IN MULTIPLE SCLEROSIS.]
Muscle Hypotonia
IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
Muscular Dystrophies
[Serum enzyme dynamics in progressive muscular dystrophies]
Muscular Dystrophy, Duchenne
[Reevaluation of serum isocitrate dehydrogenase concentration as liver function marker in patients with Duchenne muscular dystrophy]
Myelodysplastic Syndromes
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.
Isocitrate dehydrogenase mutations in myeloid malignancies.
Methylation level of Rap1GAP and the clinical significance in MDS.
Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Myocardial Infarction
CHANGES IN SERUM ISOCITRATE DEHYDROGENASE IN MYOCARDIAL INFARCTION.
Glycylprolyl-p-nitroanilidase in hepatobiliary disease.
Resveratrol protects left ventricle by increasing adenylate kinase and isocitrate dehydrogenase activities in rats with myocardial infarction.
Myocarditis
[The effect of guanosyl-5'-monophosphate on metabolic processes in rats with experimental myocarditis]
Neoplasm Metastasis
Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients.
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Neoplasm, Residual
Frontline treatment of acute myeloid leukemia in adults.
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Neoplasms
18F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience.
18F-Fluorocholine PET/CT in the Prediction of Molecular Subtypes and Prognosis for Gliomas.
2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.
5-hydroxymethylcytosine and its potential roles in development and cancer.
A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma.
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
A highly facile and specific assay for cancer-causing isocitrate dehydrogenase mutant using 13C4-labeled ?-ketoglutarate and heteronuclear NMR.
A machine learning-based survival prediction model of high grade glioma by integration of clinical and dose-volume histogram parameters.
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
A novel truncated form of HMGA2 in tumors of the ovaries.
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
A Prognostic Microenvironment-Related Immune Signature via ESTIMATE (PROMISE Model) Predicts Overall Survival of Patients With Glioma.
A Rare Case of Atypical Pleomorphic Neoplasm of Pineal Region in a Child: A Case Report.
A vaccine targeting mutant IDH1 induces antitumour immunity.
Aberrant IDH3? expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis.
Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients.
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Absence of IDH mutation in colorectal cancers with microsatellite instability.
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation.
Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea.
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
Altered Motor Excitability in Patients With Diffuse Gliomas Involving Motor Eloquent Areas: The Impact of Tumor Grading.
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.
Analysis of Cellular Feature Differences of Astrocytomas with Distinct Mutational Profiles Using Digitized Histopathology Images.
Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.
Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia.
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells.
Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.
Astrocytic gliomas WHO grades II and III.
ATRX immunostaining predicts IDH and H3F3A status in gliomas.
BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.
Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Biochemical changes in endometrial carcinoma and their correlation to clinical outcome and prognosis.
Biochemical markers of central nervous system tumors measured in cerebrospinal fluid and their potential use in diagnosis and patient management: a review.
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches.
Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery.
Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases.
Cancer metabolism as a central driving force of glioma pathogenesis.
Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases.
Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.
Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas.
Chromatographic methods coupled to mass spectrometry for the determination of oncometabolites in biological samples-A review.
Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1).
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Clinical Management of Diffuse Low-Grade Gliomas.
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma.
Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns.
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens.
Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells.
Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
Deletions on Chromosome Y and Downregulation of the SRY Gene in Tumor Tissue Are Associated with Worse Survival of Glioblastoma Patients.
Detecting isocitrate dehydrogenase gene mutations in oligodendroglial tumors using diffusion tensor imaging metrics and their correlations with proliferation and microvascular density.
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis.
Detection of Isocitrate Dehydrogenase Mutated Glioblastomas Through Anomaly Detection Analytics.
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?
Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Diagnostic and prognostic potential of serum cell-free microRNA-214 in glioma.
Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival.
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
Dual-layer detector spectral CT-a new supplementary method for preoperative evaluation of glioma.
Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18 F]FDG.
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Effective use of small-interfering RNA to characterize residual B-cell non-Hodgkin lymphoma cells following chemotherapy.
Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-grade gliomas -A Potential Therapy for IDH Wild-type Recurrent High-grade Gliomas.
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Emerging biomarkers in glioblastoma.
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Enzyme activities of six different dehydrogenases in Ehrlich ascites cells measured by flow cytometry.
Enzymes in cancer. 2. The isocitric dehydrogenase of the cerebrospinal fluid in various cancerous and noncancerous conditions.
Epigenetic aberrations in myeloid malignancies (Review).
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells.
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.
Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.
Familial hematological malignancies: new IDH2 mutation.
Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive IDH flux.
Fisetin modulates mitochondrial enzymes and apoptotic signals in benzo(a)pyrene-induced lung cancer.
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Fumarate hydratase in cancer: A multifaceted tumour suppressor.
GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis.
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment.
Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone.
Glioblastoma.
Glioblastoma: from volumetric analysis to molecular predictors.
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Glioma grading, molecular feature classification, and microstructural characterization using MR diffusional variance decomposition (DIVIDE) imaging.
Glioma.
Glioneuronal tumours with features of rosette-forming glioneuronal tumours of the fourth ventricle and dysembryoplastic neuroepithelial tumours: a report of three cases.
GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.
Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma.
Heterogeneity of tumor-induced gene expression changes in the human metabolic network.
Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas.
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
HISTOCHEMICAL STUDIES ON THE LOCALIZATION OF ISOCITRIC DEHYDROGENASE IN HUMAN TUMORS.
Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.
Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas.
Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.
Identification of IDH and TERTp mutation status using 1 H-MRS in 112 hemispheric diffuse gliomas.
Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status.
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
IDH-Mutant Brain Tumors Hit the Achilles' Heel of Macrophages with R-2-Hydroxyglutarate.
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
IDH1 Expression via the R132H Mutation-Specific Antibody in Adrenocortical Neoplasias-Prognostic Impact in Carcinomas.
IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
IDH1 mutations in gliomas: when an enzyme loses its grip.
IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity.
IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1?mutant tumor cells.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1?-regulated pseudohypoxic state.
IFI30 expression is an independent unfavourable prognostic factor in glioma.
Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype.
Immunohistochemical and molecular genetics study of a granular cell astrocytoma: A case report of malignant transformation to a glioblastoma.
Immunotherapy in gliomas: Are we reckoning without the innate immunity?
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer.
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer.
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas.
Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry.
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.
Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration.
Intraventricular Glioblastomas.
In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Isocitrate Dehydrogenase (IDH) Inhibition as Treatment of Myeloid Malignancies: Progress and Future Directions.
Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.
Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Isocitrate dehydrogenase mutations in myeloid malignancies.
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
Isoenzymes of isocitrate dehydrogenase in cytoplasm of human cancer cells.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
Kinase Networks Regulate Metabolism: I'D(H1) Never Have Guessed!
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Low-grade gliomas.
Low-grade Gliomas.
Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas.
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Magnetic resonance metabolic imaging of glioma.
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.
Metabolic modulation of cancer: a new frontier with great translational potential.
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity.
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.
Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma.
Molecular targeted therapy of glioblastoma.
MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
MRI-Based Radiomics and Radiogenomics in the Management of Low-Grade Gliomas: Evaluating the Evidence for a Paradigm Shift.
Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas.
Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study.
Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Mutant IDH is sufficient to initiate enchondromatosis in mice.
Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Mutant IDH1 regulates the tumor-associated immune system in gliomas.
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Mutation of IDH1 aggravates the fatty acid?induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain.
Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells.
Myeloproliferative neoplasms: Current molecular biology and genetics.
Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.
Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.
Oncometabolites in cancer aggressiveness and tumour repopulation.
Overexpression of MTH1 and OGG1 proteins in ulcerative colitis-associated carcinogenesis.
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping.
Papilloedema secondary to oligodendroglioma.
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Pediatric glioblastoma with oligodendroglioma component: Aggressive clinical phenotype with distinct molecular characteristics.
Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes.
Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET.
Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival.
Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making.
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas.
Prognostic Importance of Age, Tumor Location, and Tumor Grade in Grade II Astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and the Surveillance, Epidemiology, and End Results Database.
Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Protein Markers Predict Survival in Glioma Patients.
Proteomic profiling of differential display analysis for human oral squamous cell carcinoma: 14-3-3 ? Protein is upregulated in human oral squamous cell carcinoma and dependent on the differentiation level.
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer.
Rare insights into cancer biology.
Reasons for optimism in the therapy of acute leukemia.
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Recent aspects of classification and epidemiology of epilepsy-associated tumors.
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.
Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
Relationship of Molecular Genetic Tumor Marker IDH with Oxidative Status in Gliomas.
Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
Revisiting the TCA cycle: signaling to tumor formation.
Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma.
Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study.
Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Role of mitochondrial dysfunction in cancer progression.
Roles of IDH1/2 and TET2 mutations in myeloid disorders.
S-2-hydroxyglutarate regulates CD8
Sclerosing stromal tumor of the ovary. A light, electron microscopic and enzyme histochemical study.
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).
Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes.
Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication.
SOHO State of the Art Updates and Next Questions: IDH Inhibition.
Solitary primary intracranial leptomeningeal glioblastoma invading the normal cortex: Case report.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
Studies on the isocitrate dehydrogenase. II. Isocitrate dehydrogenase and transhydrogenase in tumor bearing rat liver and ascites tumor cells.
Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study.
Survival trends in glioma: Experience at a tertiary care centre.
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Targeting cancer metabolism.
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Targeting isocitrate dehydrogenase (IDH) in cancer.
Targeting isocitrate dehydrogenase mutations in cancer: emerging evidence and diverging strategies.
Targeting metabolic pathways for head and neck cancers therapeutics.
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State.
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).
TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study.
TET proteins and the control of cytosine demethylation in cancer.
The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The clinical use of IDH1 and IDH2 mutations in gliomas.
The effectiveness of salvage treatments for recurrent lesions of oligodendrogliomas previously treated with upfront chemotherapy.
The functional roles of TCA cycle metabolites in cancer.
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
The implications of IDH mutations for cancer development and therapy.
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia.
The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation.
The prognostic impact of ventricular opening in glioblastoma surgery: a retrospective single center analysis.
The Relationship Between Stimulation Current and Functional Site Localization During Brain Mapping.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The role of deep learning-based survival model in improving survival prediction of patients with glioblastoma.
The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
The Roles of 2-Hydroxyglutarate.
The studies on glycolytic enzymes in relation to cancer. II. Comparative study of phosphohexose-isomerase, aldolase, isocitric dehydrogenase, serum glutamic oxaloacetic and pyruvic transaminase, and alkaline phosphatase in liver.
Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer.
Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Treatment Strategies for Low-Grade Glioma in Adults.
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism.
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.
Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment.
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Update on molecular findings, management and outcome in low-grade gliomas.
Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.
Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations.
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of
Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism.
Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.
Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1.
World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.
World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.
[Activity of isocitrate dehydrogenase in breast cancer]
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
[Isomerase phosphohexose, isocitric dehydrogenase, and alkaline phosphatase in cancer patients]
[Personalized treatment of cholangiocellular carcinoma (CCA)].
[Research on molecular markers for epigenetic changes in myeloid malignancies].
[Studies on the recording of cytostatic effects on organ cultures of squamous cell carcinoma of the uterine cervix]
[Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Nephrotic Syndrome
Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome.
Nervous System Diseases
Isocitric dehydrogenase activity of the cerebrospinal fluid of children with neurologic disorders.
Neuroblastoma
Mitochondrial isocitrate dehydrogenase protects human neuroblastoma SH-SY5Y cells against oxidative stress.
Non-alcoholic Fatty Liver Disease
IDH2 Deficiency Aggravates Fructose-Induced NAFLD by Modulating Hepatic Fatty Acid Metabolism and Activating Inflammatory Signaling in Female Mice.
Obesity
Increased obesity resistance and insulin sensitivity in mice lacking the isocitrate dehydrogenase 2 gene.
Oligodendroglioma
Anaplastic Oligodendroglioma with Transdural Extension.
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
Clinical implications of molecular analysis in diffuse glioma stratification.
Clinical importance of molecular markers of adult diffuse glioma.
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry.
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
FISHing for 1p19q codel in oligodendroglioma.
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas.
IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
IDH-1 polymorphisms in pilocytic astrocytomas.
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Lower Grade Gliomas.
Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis by MicroRNA183-mediated inhibition of Semaphorin 3E.
Mutant metabolic enzymes are at the origin of gliomas.
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Promoter Methylation Analysis of IDH Genes in Human Gliomas.
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
[Basic principles of diagnosis and treatment of gliomas].
Osteosarcoma
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Pancreatic Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Paraganglioma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Paraproteinemias
IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma.
Peptic Ulcer
Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis.
Periodontitis
Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis.
Pheochromocytoma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Prostatic Hyperplasia
Isocitrate dehydrogenase activity in untreated and treated benign prostatic hypertrophy and adenocarcinomatous prostate.
Prostatic Neoplasms
Genetics of Prostate Carcinoma.
Modulation of hypoxia-inducible factor-1? expression by mitochondrial NADP(+)-dependent isocitrate dehydrogenase.
Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Targeting cancer metabolism.
Psoriasis
Epidermal activity of NAD-dependent isocitrate dehydrogenase in psoriasis during treatment with dithranol.
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Pyelonephritis
[Serum and urine isocitrate dehydrogenase activity in patients with chronic pyelonephritis]
Reperfusion Injury
Mitochondrial NADP(+)-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury.
Retinal Degeneration
A novel missense variant in IDH3A causes autosomal recessive retinitis pigmentosa.
Mouse Idh3a mutations cause retinal degeneration and reduced mitochondrial function.
Retinitis Pigmentosa
A novel missense variant in IDH3A causes autosomal recessive retinitis pigmentosa.
Whole-Exome Sequencing Identifies Biallelic IDH3A Variants as a Cause of Retinitis Pigmentosa Accompanied by Pseudocoloboma.
Retinoblastoma
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Reye Syndrome
Serum isocitrate dehydrogenase activity in Reye's syndrome.
Sarcoma
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Targeting cancer metabolism.
Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Sarcoma, Ewing
Current questions in bone sarcomas.
Schistosomiasis
Serum isocitric dehydrogenase and glutamic dehydrogenase in schistosomiasis.
Seizures
Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches.
IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas.
IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
Isocitrate dehydrogenase mutations: A biomarker for glioma-related excitability and seizures.
Seminoma
Modified expression of cytoplasmic isocitrate dehydrogenase electrophoretic isoforms in seminal plasma of men with sertoli-cell-only syndrome and seminoma.
Small Cell Lung Carcinoma
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Starvation
Biochemical characterization of NADP(+)-dependent isocitrate dehydrogenase from Microcystis aeruginosa PCC7806.
Metabolic and ultrastructural responses of lupine embryo axes to sugar starvation.
Physiological regulation of isocitrate dehydrogenase and the role of 2-oxoglutarate in Prochlorococcus sp. strain PCC 9511.
Stomach Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Isocitrate Dehydrogenase 2 Dysfunction Contributes to 5-hydroxymethylcytosine Depletion in Gastric Cancer Cells.
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer.
Tauopathies
Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis.
Thyroid Cancer, Papillary
Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma.
Thyroid Neoplasms
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Targeting cancer metabolism.
Triple Negative Breast Neoplasms
Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
Tuberculosis
Cloning, expression, purification, crystallization and preliminary X-ray crystallographic analysis of isocitrate dehydrogenase 2 (Rv0066c) from Mycobacterium tuberculosis.
Comparison of Mycobacterium tuberculosis isocitrate dehydrogenases (ICD-1 and ICD-2) reveals differences in coenzyme affinity, oligomeric state, pH tolerance and phylogenetic affiliation.
Development of mycobacterial species-specific DNA probes by subtraction hybridization.
Further studies with isocitric dehydrogenase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Identification, molecular cloning, and evaluation of potential use of isocitrate dehydrogenase II of Mycobacterium bovis BCG in serodiagnosis of tuberculosis.
Isocitric dehydrogenase and nicotinamide adenine dinucleotidase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Purification and characterisation of isocitrate dehydrogenase and malate dehydrogenase from Mycobacterium tuberculosis and evaluation of their potential as suitable antigens for the serodiagnosis of tuberculosis.
Urinary Bladder Neoplasms
Identification of differentially expressed proteins during human urinary bladder cancer progression.
Uterine Hemorrhage
Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium.
Venous Thromboembolism
Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Viremia
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein.
Weil Disease
[The value of isocitric dehydrogenase in the differential diagnosis between viral hepatitis and Weil's disease.]
Whooping Cough
A Functional Tricarboxylic Acid Cycle Operates during Growth of Bordetella pertussis on Amino Acid Mixtures as Sole Carbon Substrates.